B. Metzler seel. Sohn & Co. Holding AG Takes $1.90 Million Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

B. Metzler seel. Sohn & Co. Holding AG purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the 3rd quarter, HoldingsChannel.com reports. The fund purchased 33,183 shares of the biopharmaceutical company’s stock, valued at approximately $1,899,000.

A number of other large investors have also recently bought and sold shares of HALO. Boston Trust Walden Corp acquired a new stake in shares of Halozyme Therapeutics during the second quarter worth about $23,211,000. CANADA LIFE ASSURANCE Co lifted its position in Halozyme Therapeutics by 29.5% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 130,856 shares of the biopharmaceutical company’s stock worth $5,321,000 after acquiring an additional 29,845 shares during the period. Swedbank AB purchased a new position in shares of Halozyme Therapeutics in the 1st quarter valued at approximately $13,927,000. Creative Planning increased its holdings in shares of Halozyme Therapeutics by 43.2% in the second quarter. Creative Planning now owns 37,291 shares of the biopharmaceutical company’s stock valued at $1,953,000 after purchasing an additional 11,249 shares during the period. Finally, Boston Partners raised its stake in shares of Halozyme Therapeutics by 14.1% during the first quarter. Boston Partners now owns 630,368 shares of the biopharmaceutical company’s stock worth $25,500,000 after purchasing an additional 77,976 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on HALO shares. Benchmark reiterated a “buy” rating and issued a $60.00 price objective on shares of Halozyme Therapeutics in a research report on Thursday, August 8th. Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. TD Cowen raised their price objective on shares of Halozyme Therapeutics from $59.00 to $65.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. HC Wainwright reiterated a “buy” rating and set a $68.00 target price on shares of Halozyme Therapeutics in a research report on Wednesday. Finally, JPMorgan Chase & Co. cut Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and raised their price target for the company from $52.00 to $57.00 in a report on Thursday, September 19th. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $61.11.

Halozyme Therapeutics Stock Down 0.1 %

Shares of NASDAQ:HALO opened at $45.70 on Friday. The company has a market capitalization of $5.81 billion, a P/E ratio of 15.13, a P/E/G ratio of 0.41 and a beta of 1.29. The stock’s fifty day simple moving average is $55.15 and its 200-day simple moving average is $53.48. Halozyme Therapeutics, Inc. has a 52-week low of $33.15 and a 52-week high of $65.53. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $62.03, for a total value of $620,300.00. Following the completion of the transaction, the senior vice president now directly owns 173,756 shares in the company, valued at approximately $10,778,084.68. The trade was a 5.44 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In the last ninety days, insiders have sold 60,000 shares of company stock worth $3,425,000. Corporate insiders own 2.40% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.